Current Edition

2018

Lilly to Present Phase 3 Data at AHS 2018 Highlighting Innovative Potential Treatments for Migraine and Cluster Headache

Eli Lilly and Company (NYSE: LLY) announced today it will present Phase 3 data for galcanezumab and lasmiditan, two investigational, non-opioid treatments for migraine and cluster …

Continue Reading →
announces

NANOBIOTIX ANNOUNCES POSITIVE PHASE II/III TOPLINE DATA IN SOFT TISSUE SARCOMA WITH NBTXR3

Trial achieved its primary endpoint of pathological Complete Response Rate Trial achieved its secondary endpoint in operability (R0 rate) NBTXR3 demonstrated significant superiority and clinical …

Continue Reading →
2018

ASCO 2018: CarThera presents promising preliminary efficacy data for treating recurrent glioblastoma

Preliminary data from the first clinical trial of the company’s intracranial ultrasound implant, SonoCloud®, show a good safety profile and promising trends in overall survival …

Continue Reading →
bolster

Patient Registries to Bolster Cell- and Gene-Therapy Clinical Trial Data

As the first personalized cell and gene therapies are approved from small clinical trials, researchers propose the creation of publicly accessible databases to pull together …

Continue Reading →
ARC-520

Arrowhead Pharmaceuticals Presents ARC-520 Clinical Data at The International Liver Congress™

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced the presentation of clinical data on ARC-520, the company’s prior generation investigational medicine for the treatment of chronic …

Continue Reading →
brain

Brain Healthcare Innovator ElMindA Adopting Smart Data

Pilots MEDEI’s SMART-TRIAL data management platform to better document the efficacy and safety of its brain network activation technology One of the world’s leading neuro …

Continue Reading →
data

Semaglutide Injection Phase 2 Data Presented at ENDO Demonstrated Significant Weight Loss in Adults With Obesity

Adults with obesity treated with semaglutide 0.4 mg administered once-daily via subcutaneous injections lost up to 13.8% of their body weight after 52 weeks in …

Continue Reading →
ADC

Daiichi Sankyo Presents Updated Data for DS-8201 in Patients with HER2-Expressing Gastric Cancer at ASCO 2018 Gastrointestinal Cancers Symposium

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that updated phase 1 safety and efficacy data for DS-8201, an investigational HER2-targeting antibody drug conjugate …

Continue Reading →
analytics

AEGLE Platform Demonstrations: Big Data analytics in Healthcare

In February 20th and 22nd and March 15th, Aegle is launching a series of webinars with the objective of demonstrating how the final prototype of the AEGLE …

Continue Reading →
clinic

New Analysis Shows High Rates of Skin Clearance as Measured by Absolute PASI in Patients With Moderate to Severe Plaque Psoriasis Treated With Janssen’s TREMFYA® (guselkumab)

Janssen-Cilag International NV (“Janssen”) presented a new analysis from VOYAGE 1 assessing efficacy responses based on absolute Psoriasis Area and Severity Index score (PASI), as …

Continue Reading →